# US 2018/0021350 A1 · Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021350 A1
- Document ID: US20180021350A1
- Status: Published application
- Kind: A1
- Application number: 15/723,963
- Filed: 2017-10-03
- Published: 2018-01-25
- Earliest claimed: 2005-04-15
- Assignees: Clarus Therapeutics, Inc.
- Applicants: Clarus Therapeutics, Inc.
- Inventors: Robert E. DUDLEY; Panayiotis P. CONSTANTINIDES
- Web page: https://patentgrep.com/patent/US20180021350A1

## CPC

- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/4858: {Organic compounds}
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 5/24: of the sex hormones
- A61P 5/26: Androgens
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/16: Masculine contraceptives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07J 1/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.

## Claims

### Claim 1

An oral pharmaceutical formulation comprising:
(a) about 23 wt. % or less of a testosterone ester selected from the group consisting of testosterone enanthate, testosterone undecanoate, testosterone cypionate and testosterone palmitate,
(b) lipophilic surfactant, and
(c) polyoxyethylene 40 hydrogenated castor oil,
wherein the weight ratio of the lipophilic surfactant to polyoxyethylene 40 hydrogenated castor oil ranges from 3.8:1 to 4.2:1.

### Claim 2 (depends on 1)

The oral pharmaceutical formulation of claim 1, wherein the lipophilic surfactant is selected from the group consisting of glyceryl palmitostearate, glyceryl monolinoleate and mixtures thereof.

### Claim 3 (depends on 2)

The oral pharmaceutical formulation of claim 2, wherein the lipophilic surfactant is glyceryl monolinoleate.

### Claim 4 (depends on 1)

The oral pharmaceutical formulation of claim 1, wherein the testosterone ester is present in the formation at from about 10 wt. % to about 23 wt. % thereof.

### Claim 5 (depends on 1)

The oral pharmaceutical formulation of claim 1, wherein the testosterone ester is testosterone undecanoate.

### Claim 6 (depends on 1)

The oral pharmaceutical formulation of claim 1, wherein the formulation is encased in a capsule.
